3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
6
Prostatic Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Myeloid, Acute
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Recurrence
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lung Neoplasms
3
Thrombosis
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Esophageal Squamous Cell Carcinoma
2
Disease
2
Carcinoma, Transitional Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombophilia
1
Thrombocytopenia
1
Thoracic Neoplasms
1
Skin Neoplasms
1
Pituitary Neoplasms
1
Pediatric Solid Tumor, Unspecified, Protocol Specific
1
Interventions
lanreotide
1
Solutions
1
Radiosurgery
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Growth Hormone-Secreting Pituitary Adenoma
×
Injections
×
Clear all
NCT03439709
2018-03-01
MERGE
Samsung Medical Center
Phase 3
Unknown
90 enrolled